News - Immunologicals

Filter

Current filters:

Immunologicals

Popular Filters

90 to 114 of 129 results

News briefs: setbacks for B-MS hep C drug; Baxter's HyQ

02-08-2012

US drug major Bristol-Myers Squibb (NYSE: BMY) has suspended study drug administration in ongoing Phase…

Anti-viralsBaxter InternationalBMS-986094Bristol-Myers SquibbHyQImmunologicalsNorth AmericaPharmaceuticalRegulationResearch

ALK Abello partner Torii progresses Japanese development of Mitizax

01-08-2012

Denmark-based allergy specialist ALK Abello (ALKB: DC) revealed yesterday that its strategic partner,…

ALK AbelloImmunologicalsMitizaxPharmaceuticalResearchRespiratory and PulmonaryTorii Pharma

Barriers to overcome in lupus drug development

22-07-2012

It has taken the lupus research community over 50 years to produce a new therapy. Although it is now…

Anthera PharmaceuticalsBenlystaBiotechnologyblisibimodGlaxoSmithKlineImmunologicalsPharmaceuticalResearch

Rapamycin raises cognition throughout life span, study in mice shows

02-07-2012

Cognitive skills such as learning and memory diminish with age in everyone, and the drop-off is steepest…

ImmunologicalsNeurologicalPfizerPharmaceuticalrapamycinResearchsirolimus

Positive interim clinical data in allergic children treated with Viaskin Peanut

19-06-2012

French allergy specialist DBV Technologies (Euronext: DBV), creator of Viaskin, a new standard in the…

DBV TechnologiesImmunologicalsPharmaceuticalResearchViaskin

Osiris gets second approval for Prochymal, in New Zealand

15-06-2012

USA-based Osiris Therapeutics (Nasdaq: OSIR) has received a second approval to market its first-in-class…

Asia-PacificBiotechnologyImmunologicalsOsiris TherapeuticsProchymalRegulation

Positive long-term results for Bristol-Myers Squibb's Nulojix in organ rejection

06-06-2012

US drug major Bristol-Myers Squibb (NYSE: BMY) yesterday presented the data at the 2012 American Transplant…

Bristol-Myers SquibbImmunologicalsNulojixPharmaceuticalResearch

InterMune to divest Actimmune for $55 million; to focus on Esbriet

22-05-2012

California, USA-based biotech firm InterMune (Nasdaq: ITMN) says that it has reached a definitive agreement…

ActimmuneBiotechnologyEsbrietFinancialImmunologicalsInterMuneMergers & AcquisitionsRespiratory and PulmonaryVidara Therapeutics

World's first stem cell drug, Osiris' Prochymal, approved in Canada

21-05-2012

USA-based Osiris Therapeutics (Nasdaq: OSIR) has received market authorization from Health Canada to…

BiotechnologyImmunologicalsNorth AmericaOsiris TherapeuticsProchymalRegulation

Cell Therapeutics to acquire pacritinib, a potential myelofibrosis drug

20-04-2012

US biotech firm Cell Therapeutics (Nasdaq and MTA: CTIC) and Singapore-based S*BIO Pte have entered into…

BiotechnologyCell TherapeuticsImmunologicalsLicensingOncologypacritinibS*BIO

Halozyme plunges as FDA call for more data on HyQ BLA

17-04-2012

USA-based Halozyme Therapeutics saw its shares plummet 24% to $8.56 by close of trading yesterday, after…

Baxter InternationalBiotechnologyHalozyme TherapeuticsHyQImmunologicalsNorth AmericaRegulation

GlaxoSmithKline links with Japan's Chiome on MAbs

10-04-2012

UK pharma giant GlaxoSmithKline group (LSE: GSK) and Tokyo, Japan-based biotech-venture company Chiome…

BiotechnologyChiome BioscienceGlaxoSmithKlineImmunologicalsLicensingOncologyPharmaceuticalResearch

Novartis expands transplant portfolio with first branded generic tacrolimus

04-04-2012

Swiss drug major Novartis has announced the US introduction and availability of Hecoria (tacrolimus)…

Astellas PharmaGenericsHecoriaImmunologicalsMarkets & MarketingNorth AmericaNovartisPrografSandoztacrolimus

Recalls threaten public confidence in vaccines and immunoglobulins

27-03-2012

Quality defects and donor tissue history must be more carefully monitored to increase public acceptance…

BiotechnologyHealthcareImmunologicalsRegulationVaccines

Ablynx extends Nanobody deal with Boehringer

21-03-2012

Belgian drug developer Ablynx (Euronext Brussels: ABLX) yesterday announced a two-year extension of the…

AblynxBiotechnologyBoehringer IngelheimImmunologicalsLicensingOncologyPharmaceuticalRespiratory and Pulmonary

FDA calls for more data on Merck combo drug; Good results with allergy drug

06-03-2012

The US Food and Drug Administration (FDA) has issued a Complete Response Letter to drug giant Merck &…

ALK AbelloatorvastatinCardio-vascularezetimibeImmunologicalsMerck & CoNorth AmericaPharmaceuticalRegulationResearch

Sanofi surprises Osiris by pulling out of Prochymal deal

13-02-2012

Maryland, USA-based Osiris Therapeutics (Nasdaq: OSIR) has provided an update on the status of the development…

GenzymeImmunologicalsLicensingOsiris TherapeuticsPharmaceuticalProchymalSanofi

Otsuka Pharma and UCB re-focus collaboration

16-01-2012

Japan’s Otsuka Pharmaceutical (TYO: 4768) and Belgian drugmaker UCB (Euronext Brussels: UCB) have…

Asia-PacificCimziaImmunologicalsKeppraLicensingNeurologicalOtsukaPharmaceuticalResearchrotigotineUCB

FDA gives Hemispherx time to respond to CRL

12-01-2012

Shares of USA-based Hemispherx Biopharma (NYSE Amex: HEB) rose 14% to $0.24 on Wednesday, after the company…

AmpligenHemispherx BioPharmaImmunologicalsNorth AmericaPharmaceuticalRegulation

UCB and Immunomedics amend epratuzumab accord

29-12-2011

New Jersey, USA-based Immunomedics (Nasdaq: IMMU) and Belgian drugmaker UCB (Euronext Brussels: UCB)…

epratuzumabImmunologicalsImmunomedicsLicensingPharmaceuticalRare diseasesUCB

Karo Bio skyrockets on deal with Pfizer

28-12-2011

Sweden’s Karo Bio (STO: KARO) saw its shares rocket 80% to 1.67 Swedish ronor on December 24, after…

Anti-Arthritics/RheumaticsImmunologicalsKaro BioLicensingNeurologicalPfizerPharmaceuticalResearch

Ablynx earns milestone from Merck Serono

13-12-2011

Belgium’s Ablynx (Euronext Brussels: ABLX) says it will earn a 1 million-euro ($1.3 million) from…

AblynxBiotechnologyFinancialImmunologicalsMerck KGaAMerck SeronoPharmaceuticalResearch

Number of monoclonal antibody products in development continues to increase, says Tufts CSDD

09-11-2011

Developers are steadily increasing the number of monoclonal antibody products - known as MAbs - for which…

BiotechnologyImmunologicalsOncologyResearch

EMA says risk-benefit of ARBs positive; acts on Advagraf and Protelos/Osseor

21-10-2011

In a flurry of late news yesterday from the European Medicines Agency and its Committee for Medicinal…

AdvagrafAnti-Arthritics/RheumaticsAstellas PharmaCardio-vascularEuropeImmunologicalsPharmaceuticalProtelosRegulationServier

90 to 114 of 129 results

Back to top